Skip to main content
Premium Trial:

Request an Annual Quote

No Deal

Genzyme rejected Sanofi-Aventis' $18.5 billion buyout offer, the New York Times reports. In a letter to Sanofi's Christopher Viehbacher, Genzyme chief executive Henri Termeer says that the $69-a-share offer "provides no new information and no improvement in price, and therefore fails to establish a basis for engagement by the Genzyme board." The Genzyme board, Agence-France Presse notes, had turned down an offer earlier this month, too. "The 'bear hug' letter left open the possibility of discussions between company executives and is typically considered a less aggressive step than going hostile," the Wall Street Journal says, but adds that Sanofi says it is "prepared to consider all alternatives to successfully complete this transaction."

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.